CX 717
Sign in to saveAlso known as CX717, CX-717
CX717 is an ampakine compound created by Christopher Marrs and Gary Rogers in 1996 at Cortex Pharmaceuticals. It affects the neurotransmitter glutamate, with trials showing the drug improves cognitive functioning and memory.
Wikidata facts
- Subclass of
- chemical compound
Show 1 more fact
- subject has role
- Ampakine
Sources (1)
via Wikidata · CC0
~5 min read
Encyclopedic overview
6 sectionsContents
- Approval process
- Use for reversal of respiratory depression
- Related AMPAkines
- See also
- References
- Further reading
CX717 is an ampakine compound created by Christopher Marrs and Gary Rogers in 1996 at Cortex Pharmaceuticals. It affects the neurotransmitter glutamate, with trials showing the drug improves cognitive functioning and memory.
==Approval process== In 2005 the U.S. Food and Drug Administration (FDA) accepted Cortex Pharmaceuticals' Investigational New Drug (IND) application to initiate pilot Phase II clinical trials in the United States.
Excerpted from Wikipedia’s “CX 717” article, available under the CC BY-SA 4.0 licence.